Dr. Ritu Bagla, MD

Dr. Bagla practices at Lahey Clinic in Burlington, Massachusetts, part of Beth Israel Lahey Health.

Dr. Bagla's NPI, 1043486632, was assigned on May 2, 2008. Dr. Bagla graduated from St. George's University School of Medicine in 2002. Dr. Bagla holds Massachusetts license 237362.

Dr. Bagla's primary practice is Lahey Clinic, at 41 & 45 Mall Road, Burlington, MA 01803 in Middlesex County. The practice phone is (781) 744-5100.

Dr. Bagla's primary practice is Lahey Clinic in Burlington, Massachusetts, part of Beth Israel Lahey Health. Dr. Bagla is also affiliated with Beverly Hospital. The medical group on file is Lahey Clinic. Dmand AI also links Dr. Bagla to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bagla practices, 3 sites in all. Vendor and product names are available with a free account.

Clinical neurophysiology is Dr. Bagla's primary specialty in the NPI Registry, under taxonomy code 2084N0600X. Dr. Bagla is board certified in clinical neurophysiology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Bagla's licenses on file in 3 states: Massachusetts, Florida and Pennsylvania.

Dmand AI lists alzheimer's disease, encephalopathy, epilepsy, migraine and chronic headache, mobility impairment, non-alzheimer's dementia (chronic), seizures and traumatic coma among the conditions Dr. Bagla treats.

CMS data shows 832 Medicare services from Dr. Bagla across 10 procedure codes in 2024, for 404 Medicare patients. Medicare paid $74,007 for them.

CMS counts 404 Medicare patients who saw Dr. Bagla in 2024. The largest group is 75 to 84, with 138 patients. 69% of them have high cholesterol, and 67% have high blood pressure. 36% are also on Medicaid. Their average risk score is 1.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bagla's median patient age at 65, with 51% women.

In 2024, Dr. Bagla wrote 3,248 Medicare Part D claims for 307 patients. 86% of them were for generic drugs. CMS names the drug for 3,125 of them, across 41 drugs with 11 or more claims each, at $465,724 in total drug cost. In 2023, CMS named 2,912 claims across 39 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Bagla for performance year 2024, reported through an alternative payment model (APM). Dr. Bagla accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bagla as offering telehealth.

Dmand AI links 10 papers to Dr. Bagla. The most frequent topics are Sodium Chloride, Taste Threshold and Electroencephalography. Dr. Bagla has published most often in Physiol Behav. Dr. Bagla's most frequent co-authors are Srikanth Muppidi, MD, Maromi Nei, MD and Annette F. Okai, MD.

CMS Open Payments shows 2 general payments to Dr. Bagla from 1 drug or device company from 2023 to 2024. Food and beverage make up the largest share, 100% of the total. SK Life Science, Inc. paid the most, $213.

Dr. Bagla graduated from St. George's University School of Medicine in 2002.

Dr. Bagla is in network with 11 carriers, including Blue Cross Blue Shield of Michigan, United Healthcare and Blue Cross Blue Shield of Massachusetts. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.